for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Astrazeneca Pharma India Ltd

ASTR.NS

Latest Trade

2,541.80INR

Change

49.80(+2.00%)

Volume

123,190

Today's Range

2,450.00

 - 

2,688.85

52 Week Range

1,306.05

 - 

2,809.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
2,492.00
Open
2,510.00
Volume
123,190
3M AVG Volume
0.41
Today's High
2,688.85
Today's Low
2,450.00
52 Week High
2,809.00
52 Week Low
1,306.05
Shares Out (MIL)
25.00
Market Cap (MIL)
62,300.00
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q2 2020 Astrazeneca Pharma India Ltd Earnings Release

Latest Developments

More

Astrazeneca Pharma India Gets Import, Market Permission For Dapagliflozin + Saxagliptin Film Coated Tablets

Bioton Books Impairment Loss To Affect Its H1 Net Result

Astrazeneca Pharma India June-Qtr Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited is a global biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The Company operates through two segments: Healthcare and Clinical Trial. The Healthcare segment engages in the manufacture and sale of pharmaceutical products. The Clinical Trial segment renders clinical trial services on pharmaceutical products to its group companies. It has presence in over seven areas of healthcare, including diabetes, oncology, infection, local anesthesia and maternal healthcare. The principal products/services of the Company are Meronem and Brilinta/Axcer. Its pipeline includes products, such as AZD4076, MEDI6012, AZD2811, MEDI0680, selumetinib, anifrolumab and MEDI7510. Its brands include Crestor, Seloken XL, Meronem, Arimidex, Zoladex, Nexium and Brilinta.

Industry

Major Drugs

Contact Info

Ni 12Th Floor, Manyata Empassy Business

Park Rachenahalli,Outer Ring Rd Kr Puram

Hebbal

+91.80.67748000

https://www.astrazeneca.com/country-sites/india.html

Executive Leadership

Darius Erach Udwadia

Non-Executive Independent Chairman of the Board

Rajesh Marwaha

Chief Financial Officer, Acting Compliance Officer, Whole Time Director

Pratap Rudra

Compliance Officer, Company Secretary

Gagan Singh Bedi

Managing Director, Director

Sanjay Murdeshwar

Managing Director, Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2020(E)

8.3K
EPS (INR)

2020(E)

25.340
Price To Earnings (TTM)
89.53
Price To Sales (TTM)
8.08
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
72.81
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Astrazeneca Pharma India Sept-qtr profit surges

* Profit in sept quarter last year was 8 million rupees as per ind-as; revenue from operations was 1.39 billion rupees Source text: http://bit.ly/2AbG2J4 Further company coverage:

BRIEF-Astrazeneca Pharma India gets marketing approval for combination of therapies for type 2 diabetes

* Gets marketing approval for Xigduo XR, combination of two anti-diabetic therapies for type 2 diabetes Source text: http://bit.ly/2yviJMD Further company coverage:

BRIEF-Astrazeneca Pharma India seeks shareholders' nod for appointment of Gagan Singh Bedi as MD

* Seeks shareholders' nod for for appointment of Gagan Singh Bedi as a managing director Source text - http://bit.ly/2uYHFf1 Further company coverage:

BRIEF-Astrazeneca Pharma India June-qtr profit falls

* Profit in June quarter last year was 126 million rupees as per IND-AS; total revenue was 1.42 billion rupees

BRIEF-Astrazeneca Pharma India appoints Gagan Singh Bedi as MD of co

* Says Sanjay Murdeshwar has offered to resign as managing director of company

BRIEF-Astrazeneca Pharma India gets import and market permission from DCGI for FDC of asthma drug

* Received import and market permission in form 45 from DCGI (Drug Controller General of India)for FDC of Budesonide 320 μg + Formoterol Fumarate Dihydrate 9 μg inhalation powder

BRIEF-Astrazeneca Pharma India posts March-qtr loss

* March quarter total income from operations 1.12 billion rupees

BRIEF-Pfizer enters into delegation of authority with Astrazeneca Pharma India

* Pfizer Ltd says entered into delegation of authority with Astrazeneca Pharma India

BRIEF-Astrazeneca Pharma India posts Sept-qtr profit

* Net loss in sept quarter last year was 66.9 million rupees ; net sales was 1.28 billion rupees Source text: http://bit.ly/2fWm3sR Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up